Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEUROLOGY Simoa® is not just a better way to detect CNS biomarkers It's a 1,000-times better way
The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.
Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.
QUANTERIX’ SIMOA TECHNOLOGY POWERS MORE THAN 85 PERCENT OF NEUROFILAMENT LIGHT BIOMARKER RESEARCH TO BE UNVEILED AT AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING Leading global neurology conference will feature 36 new Simoa-powered studies validating the use of Neurofilament light chain (Nf-L) as a potential diagnostic and prognostic biomarker for neurodegeneration
LEXINGTON, Mass.--(BUSINESS WIRE)--May 6, 2019-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology is the driving force behind 36 of the 42 – nearly 86 percent – Nf-L abstracts being presented at the American Academy of Neurology (AAN)’s Annual Meeting, taking place from May 4-10, 2019 in Philadelphia, PA. This year’s program represents a nearly four-fold increase in Nf-L research compared to last year, reinforcing the marker’s mounting value as a key indicator of neurodegenerative disease onset and progression.
“As the use cases for Nf-L grow, evidenced by the growing body of research presented at AAN, we believe that this biomarker is truly one of the most promising biomarkers for brain health with the power to completely transform the way diseases like Alzheimer’s, Multiple Sclerosis, Parkinson’s, and even brain injuries are diagnosed and treated,” said Kevin Hrusovsky, Chairman and CEO of Quanterix. “Nf-L has the ability to create new testing modalities for detection and treatment across numerous degenerative disease states, including some of the most difficult-to-detect conditions. Our Simoa technology helped researchers measure Nf-L accurately in blood for the first time, and it’s incredibly rewarding to see the continued impact of our technology on these and many other studies.”
This year’s AAN Annual Meeting will feature Nf-L abstracts that assess the viability of the biomarker as a reliable means to detect and monitor a range of neurodegenerative diseases in blood, including Alzheimer’s Disease, MS, ALS, spinal muscular atrophy and Huntington’s. In addition to evaluating the use of serum Nf-L as a comparable marker to traditional cerebral spinal fluid (CSF), presenters will speak to the marker’s drug development benefits for neurodegenerative clinical trials, which continue to face challenges and limitations based on using imaging or cerebrospinal fluid as endpoints. Furthermore, Nf-L is currently included in 46 active clinical trials in the US alone, demonstrating the degree to which its value for monitoring drug response has grown recently.
Quanterix’ Simoa platform is among the technologies proving integral to the study of serum Nf-L for these purposes in large part because it operates at a sensitivity level that is, on average, 1,000 times greater than traditional immunoassays. This dramatic improvement in sensitivity gives researchers unprecedented visibility into the presence of blood-based biomarkers suggestive of various neurological disorders. To date, the company’s technology has been utilized in more than 300 peer-reviewed studies, with more than 170 papers addressing neurological disorders specifically. Findings from this research demonstrate Simoa’s ability to potentially see disease progression earlier than imaging or CSF, improve treatment monitoring, and accelerate the delivery of more effective and safer drugs to market.
To learn more about Quanterix and its biomarker detection solutions, visit AAN Booth 1600. For more information on the AAN abstracts featuring Nf-L and Simoa, click here.
To learn more about Quanterix’ Nf-L assay, click here.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
News 
Market Data 
Discover 
